Almirall, S.A. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ALMRY Over the counter 2830 www.almirall.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Almirall, S.A.

Is Almirall (BME:ALM) A Bargain As Lebrikizumab Data Strengthens Its Valuation Case? - Oct 10th, 2026 2:16 am
EADV 2026: Long-Term Disease Control for up to Five Years in Patients With Moderate-to-Severe Atopic Dermatitis Treated With Lebrikizumab - Oct 1st, 2026 12:55 am
Almirall Advances Skin Science and Shares New Evidence Across Its Dermatology Portfolio at EADV 2026 - Sep 29th, 2026 11:00 pm
Non-Melanoma Skin Cancer Market: Focus on Disease Indication, Treatment Type, Country and Region, 2025-2035 - Aug 31st, 2026 3:03 am
Almirall Enters Collaboration With CrystalO for the Discovery and Development of Novel Small Molecules in Medical Dermatology - Aug 10th, 2026 12:00 am
Almirall SA (STU:E2Z) Q2 2026 Earnings Call Highlights: Strong Growth in Dermatology and ... - Jul 24th, 2026 9:01 am
Almirall SA (LBTSF) Q4 2025 Earnings Call Highlights: Strong Sales Growth and Strategic Investments - Feb 23rd, 2026 8:00 am
Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight - Feb 19th, 2026 3:31 pm